The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. AstraZeneca PLC (NASDAQ:AZN) is ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

UK-based pharmaceutical giant AstraZeneca plans to build its largest drug manufacturing facility in Virginia, creating ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.